You are using an older browser version. Please use a supported version for the best MSN experience.

How this $1.8 million drug is trying to disrupt the drug pricing system

Bluebird Bio's new drug is priced at $1.8 million. Nick Leschly, Bluebird Bio CEO, and CNBC's Meg Tirrell join 'The Exchange' to discuss Bluebird Bio's gene therapy payment program at a time when drug prices are on the rise.

CNBC

Fortune

image beaconimage beaconimage beacon